Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 3,001–3,100 of 3,116
Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?
Peyer, J. G. (2026) · Nature Aging · doi:10.1038/s43587-026-01165-4
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
AlTaweel, M., Almekhloof, S., Alkhayyal, A. K., AlRashada, J. Y., Alohaymid, M., Alshahrani, A., Alarfaj, A. W., Alqarni, T., Almoaibed, G., & Altharman, N. M. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2713476
“…that semaglutide reduced major kidney outcomes in patients with type 2 diabetes and chronic kidney disease [18], and the SELECT trial showed cardiovascular benefit of semaglutide in patients with established cardiovascular disease and overweight or obesity, independent of diabetes status [19].”
Huang, Z., THOMAS, R. J., Luo, Q., & Liu, Z. (2026) · Cardiac Research · doi:10.1097/re9.0000000000000028
Overview of weight loss medicines and practical advice for patients
Boocock, R. C. (2026) · Nursing Standard · doi:10.7748/ns.2026.e12753
IDRIS, I. R. (2024) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.89
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
Балыкова, Л. А., Владимировна, С. В., Orlova, D. A., Shokina, S. V., Esina, M. V., Yamashkina, E. I., Surina, T. A., Zorina, L. A., Shcherbakova, V. S., Zaslavskaya, K. Y., et al. (2026) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2026-14-4-410-422
Lee, H., Min, Y. W., Oh, Y. E., Kim, T., Min, B., Lee, J. H., & Rhee, P. (2026) · Biomedicines · doi:10.3390/biomedicines14091887
“Randomised trials and meta-analyses have not shown an excess malignancy signal with GLP-1 receptor agonists [6,7], whereas pharmacoepidemiologic findings for oesophageal cancer are mixed, including a Nordic case–control analysis that reported divergent associations for adenocarcinoma and squamous…”
critique of semaglutide (Wegovy®) for obesity management NICE technology appraisal TA875
Kahal, H., & Walton, C. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.439
Semaglutide mechanisms of action: the missing pieces
Verma, S., Guzik, T. J., & Cosentino, F. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag602
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01344-8
Singla, A., Kaur, G., Singh, G., Luthra, S., Lodha, C., Alneser, O., Alo, M. S., Ali, S. K. S., & Zulqarnain, M. A. (2026) · Cureus · doi:10.7759/cureus.113371
Rapport 24-09. Changement de paradigme dans les maladies cardio-néphro-métaboliques
Reach, G., & Jaffiol, C. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.10.002 · Cited by 2
Jensterle, M., & Janež, A. (2026) · Andrology · doi:10.1111/andr.70264 · Cited by 1
Shaw, L. J., Blankstein, R., & Chandrashekhar, Y. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.07.001
Xu, R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70423
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Grave, R. D., Sartirana, M., & Calugi, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-71456-6_12
Perioperative medicine: what do you need to know about new hypoglycemic drugs?
Пасечник, И. Н., Obukhova, O. A., & Leyderman, I. N. (2026) · Clinical nutrition and metabolism · doi:10.17816/clinutr713929
Losordo, L. D., Amin, G., Singla, M., Belk, S. S., Butler, K. R., Booz, G. W., & Monafo, A. (2026) · Pediatric Research · doi:10.1038/s41390-026-05038-9
Khan, S. S., Ndumele, C. E., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.007 · Cited by 4
Chabassier, A., Vittrant, B., Binon, P., Scornet, E., & Josse, J. (2026) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2026.100375 · Cited by 1
Wadhawan, R. (2025) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_12_26
Milder, T. Y., Milder, D. A., & Kam, P. C. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.12.014
Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Amoyel, M., Carette, C., Poghosyan, T., Beyec, J. L., & Gall, M. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag032
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Self-citationNatriuretic peptides are integral in reclassifying heart failure stage and risk
Wettersten, N. W., Horiuchi, Y., Daniels, L. B., Banerjee, S., Asami, M., & Tanabe, K. (2026) · Heart and Vessels · doi:10.1007/s00380-026-02680-5
Belin, M. A. F., Cruzeiro, J., Nunes, A., de Lima, L. F., Sormani, L. E., Gregolin, C. S., Tanganini, M. D., Vieira, T. A., Grandini, N. A., Siqueira, J. S. [., et al. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112889
Zhang, L. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-72309-4_49
Pharmacologic Therapy to Prevent CV Disease in High-Risk Youth
Hartz, J. C., Degen, M. G., & Ware, A. L. (2026) · Contemporary cardiology · doi:10.1007/978-3-032-14256-6_11
Risk Factors for New-Onset Atrial Fibrillation in Thai Adults with HypertensionPreprint
Limpijankit, V., Sasiprapha, T., Teza, H., Pattanateepapon, A., Siriyotha, M. S. , Boonmanunt, S. W., Attia, J., & Thakkinstian, A. (2025) · medRxiv · doi:10.1101/2025.05.07.25327197
Domingo, P., & Prieto, P. (2026) · Biomolecules · doi:10.3390/biom16091254
“Large cardiovascular outcome trials have demonstrated that semaglutide reduces major cardiovascular events in people with type 2 diabetes and in people with overweight or obesity and established cardiovascular disease [70,71].”
Prediabetes Progression in Young Adults: A Pooling Project
Rooney, M. R., He, J. H., Wang, D., Echouffo-Tcheugui, J. B., Fang, M., & Selvin, E. (2026) · Diabetes Care · doi:10.2337/dc26-0972
GLP-1 medications and health equity: when insurance access determines who benefits
Arif, S., Chaudhary, A., Ullah, S., et al. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag128
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Glucagon-like Peptide-1 Receptor Agonists and Thyroid Cancer: Myth or Reality?
Goldenberg, R. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3137
Surgical Strategies for the Management of Obesity
Au, C., Brumer, R. P., Schröer, J., & Tariq, N. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1513 · Cited by 4
Liu, X., & Wang, W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71373
Parekh, R. S., Inban, P., Thai, A., Agrawal, A., Kudaiarov, D., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102150
Endoscopic and Surgical Methods for Weight Loss
Pajtak, A., & Grama, P. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102147
Semaglutide e benefici cardiovascolari indipendenti dalla perdita di peso: analisi del trial SELECT
Munari, G. B., Albertelli, M., & Boschetti, M. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01844-9
Les différentes approches thérapeutiques de l’obésité : comparaison en termes d’efficience
Monnier, L., Halimi, S., & Colette, C. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.11.007 · Cited by 1
Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes
Mikhail, N. (2025) · Clinical Endocrinology and Metabolism · doi:10.31579/2834-8761/073
Paganelli, F. F. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.005
Trikha, A., & Khalil, M. (2026) · Journal of Anaesthesiology Clinical Pharmacology · doi:10.4103/joacp.joacp_419_26
Raghunathan, R. S., Jacobs, A. R., Gajic, Z. Z., Castiglioni, S., Dawood, N. B., Arthurs, L., Ranjbar, S., Rothberger, G. D., Seib, C. D., Prescott, J. D., et al. (2025) · Surgery · doi:10.1016/j.surg.2025.109868 · Cited by 1
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Management of Comorbid Conditions
Phillips, C. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_13
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Obesity and cardiovascular disease: Mechanistic insights and multimodal management strategies
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100729
Ferreira, V. M., & Muller, V. A. (2026) · medRxiv · doi:10.64898/2026.02.10.26345946
Empagliflozin and functional capacity in patients at risk of heart failure
Marwick, T. H. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107541
Semaglutide and the Effects of Glucagon-like Peptide-1 on Vision
Rajput, R., Chakravarti, H. N., Kesavadev, J., KOVIL, R. R., & Rajput, S. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_28_25
Hammer, Y., Arbel, R., Razi, T., Netzer, D., Weinstein, J. M., & Iakobishvili, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6768681/v1
Trends in non-coronary arterial outcomes in people with type 1 or type 2 diabetes mellitus
Mæng, M., & Gyldenkerne, C. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100890
Galavazi, M., Wallenius, V., Schnecke, V., Ericsson, Å., Björklund, H., & JENDLE, J. H. (2025) · Obesity · doi:10.1002/oby.24232 · Cited by 2
Eisa, N., & Barood, O. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.018 · Cited by 3
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
“…5.0-9.3% of total body weight 1 3 semaglutide 2.4 mg arm had 14.9% total body weight loss (-15.3 kg) compared to 2.4% (-2.6 kg) in the placebo arm after 68 weeks; semaglutide 2.4 mg also provided 20% lower risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke [86, 87 ].”
InfluentialConforti, A., Cifuentes‐González, C., Agrawal, R. V., & Agrawal, R. V. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104786 · Cited by 1
(2025) · doi:10.21203/rs.3.rs-6449183/v1 · Cited by 100
Prise en charge de l’obésité en 2024
Émile, C. (2024) · Option/Bio · doi:10.1016/s0992-5945(24)74591-7 · Cited by 2
Can we decrease the risk of complex liver surgery with the new GLP1 and GIP analogues?
Justo, I., Calatayud, M., Salamanca, J., Cámara, M., García‐Sesma, Á., & Loinaz, C. (2025) · Cirugía Española · doi:10.1016/j.cireng.2025.800264
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00146-1 · Cited by 3
“This question is especially relevant now that both treatment guidelines and commercial development strategies are increasingly organized around organ outcomes and comorbidity reduction, not weight loss alone 3,8 .”
InfluentialLiu, Q., Chen, L., Zhang, M., Wang, Z., Wang, X., Dong, Y., Wang, K., Jiang, C., & Yin, Y. (2026) · NeuroMolecular Medicine · doi:10.1007/s12017-026-08945-6
“Semaglutide ameliorates diabetes-associated cognitive decline by restoring aberrant O-GlcNAc modifi - cation (Gabery et al. 2020; T. Li et al. 2026 ; Lincoff et al. 2023).”
The cardiometabolic continuum: A new approach to prevention and care
Talwar, K. K., & Madhu, S. (2026) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams_223_2026
Ferraz, V. R., Dawoud, B., Mercier, P. A., & Mattei, T. A. (2026) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2026.100942
Confronting the Global Rise of Obesity and Cardiovascular Disease
Spatz, E. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1599
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · doi:10.2196/preprints.99738
Prevención secundaria en el paciente coronario
Sorbets, E. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)51065-6
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Skvortsov, V. V., Skvortsova, E. M., & Makhnach, D. A. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2605-04
Alam, A., Mahajan, K., Dutta, D., & Kamrul-Hasan, A. B. M. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103673
Brandt, E. J., Sonneville, K. R., Kirch, M., & Chang, T. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70079
Off-Trial: Real-World Weight Loss on Tirzepatide and SemaglutidePreprint
Erly, B. K., & Raja, S. (2026) · medRxiv · doi:10.64898/2026.07.14.26357502
Wang, L., Jiang, F., Yuan, S., Sun, J., Zhao, J., Zhou, S., Liang, J., Li, H., Song, P., Wang, S., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156711
“In fact, the beneficial cardiovascular effects of GLP-1 RAs have been demonstrated in a series of experimental and clinical studies such as LEADER [13], SUSTAIN-6 [14], SELECT [40] and HARMONY [14].”
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
The Latest Updates in Obesity Management in Primary Care
Poddar, M., & Maheshwari, A. (2024) · Canadian Primary Care Today · doi:10.58931/cpct.2024.2229
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695041
Overgaard, K. S., Mohamed, R. A., Andersen, T. R., Lambrechtsen, J., Egstrup, K., & Auscher, S. (2024) · Figshare · doi:10.6084/m9.figshare.26746697
Overgaard, K. S., Mohamed, R. A., Andersen, T. R., Lambrechtsen, J., Egstrup, K., & Auscher, S. (2024) · Figshare · doi:10.6084/m9.figshare.26746700
Ahmad, A., & Sabbour, H. M. (2024) · Figshare · doi:10.6084/m9.figshare.26695038
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I. J., Brown, K. E., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. (2024) · Figshare · doi:10.6084/m9.figshare.25201920
Continuidad asistencial en la atención clínica de la obesidad
Bretón, I., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501658 · Cited by 2
Srivastava, G., Madhar, A., & Chen, Y. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251380864
Secondary Prevention After Myocardial Infarction: Bridging Evidence to Practice
Haddad, K., Boivin‐Proulx, L., & Mansour, S. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.129
Ozempic naturel : comment augmenter son taux de GLP-1 sans médicaments
Scourboutakos, M. J. (2025) · The Conversation · doi:10.64628/aap.dadak96pc
Scourboutakos, M. J. (2025) · The Conversation · doi:10.64628/ade.unpsgqvat
Cardiac GLP1R gene expression: A cross-species single-cell transcriptomic analysis
Dostal, C., Ernst, M., Reiner, J., Snelling, R., Hu, C., Pokreisz, P., Kiss, A., & Podesser, B. K. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00113
Cardiovascular effects of incretin receptor agonists: beyond glycemic control
Ravić, M. P., Srejovic, I. M., Milosavljević, I., Novakovic, J. N., Jakovljević, V., Vučićević, K., Petrovic, D., & Muric, M. D. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2026-0184
From Adipose Tissue Dysfunction to Venous Thromboembolism
Boccatonda, A., Brighenti, A., Caturano, A., D’Ardes, D., Acierno, C., Russo, V., Conte, C., Simioni, P., & Campello, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197500
Cardiometabolic medicine in China: Burden, challenges, and strategic priorities
Zeng, R., Li, S., Wang, X., Dou, K., & Li, J.-J. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100505
Impact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review
Redavid, C., Pirro, P., Bertin, L., & Savarino, E. V. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17040057
GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
Alwaily, Z. A., Rahman, O. U., Swe, A. T., Abouayana, A., Sodhi, N. S., Goh, M. J., Ahmed, A., Natesan, T. A., Shahzad, S., Merchant, O. H., et al. (2026) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/226416
Balen, B., Bischof, E. Y., Goshen, A., Strauss, T., Haber, C., Snyder, M. P., Gladyshev, V. N., Horvath, S., Kennedy, B. K., & Pintar, N. (2026) · Research Square · doi:10.21203/rs.3.rs-11209869/v1
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Building the Business Case for Access to Obesity Treatment
Kozato, A., Orandi, B. J., Parikh, M., et al. (2026) · Obesity · doi:10.1002/oby.70305
Mauriello, A., Cetoretta, V., Giudice, C. D., Correra, A., Maratea, A. C., Gioia, R., Liccardo, B., Esposito, G., Russo, V., & D’Andrea, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102257
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
